title: IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
abstract: BACKGROUND
  Seizure commonly presents as an initial symptom and plays an important role in the clinical presentation and quality of life of patients with low-grade glioma (LGG). To date, the mechanism and genetic alterations underlying tumor-related seizures in LGG remain to be fully elucidated. Both isocitrate dehydrogenase 1/2 (IDH1/2) mutation and seizure frequently occur in patients with LGG. We set out to investigate the potential relationship between IDH1/2 mutation and presentation of seizure preoperatively, and observe whether or not IDH1/2 mutation influences seizure control postoperatively.
  
  
  METHODS
  A total of 311 adult patients with LGG were enrolled in our study with both clinical data and IDH1/2 mutation data available. IDH1/2 mutation was detected directly by pyro-sequencing. The chi-squared test was performed to determine whether the IDH1/2 mutation has any relevance to seizure onset and to evaluate the potential impact that IDH1/2 mutation may exert on seizure control postoperatively.
  
  
  RESULTS
  Seizure presented as an initial symptom in 71.4% (222/311) of patients with LGG, among which 189 patients were detected to bear IDH1/2 mutation in their tumors (P=0.035, chi-squared test). However, IDH1/2 mutation does not seem to contribute to the seizure control postoperatively (P=0.350 and 0.577 for the 6- and 12-month follow-up, respectively, chi-squared test).
  
  
  CONCLUSIONS
  IDH1/2 mutation occurs more frequently in LGG patients with seizure as an initial symptom, suggesting a potential relationship between this genetic phenotype and clinical seizure presentation. IDH1/2 mutation shows no prognostic value for postoperative seizure control.
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: zhangzhong0502@163.com.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Zhong
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Beijing Neurosurgical Institute, Beijing, China; Beijing Institute for Brain Disorders, Beijing, China. Electronic address: wangzheng1024@126.com.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Beijing Neurosurgical Institute, Beijing, China; Beijing Institute for Brain Disorders, Beijing, China. Electronic address: taylor.wang1220@gmail.com.
authors.forename: Yinyan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Beijing Neurosurgical Institute, Beijing, China; Beijing Institute for Brain Disorders, Beijing, China. Electronic address: yougan1105@sohu.com.
authors.forename: Gan
authors.initials: G
authors.lastname: You
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Beijing Neurosurgical Institute, Beijing, China; Beijing Institute for Brain Disorders, Beijing, China; National Clinical Research Center of Neurological Diseases, Beijing, China. Electronic address: taojiang1964@163.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
mesh_terms: D000328:Adult; D044466:Asian People / Q000235:genetics; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D002681:China; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D009154:Mutation; D060787:Neoplasm Grading; D012640:Seizures / Q000235:genetics* / Q000503:physiopathology / Q000601:surgery
chemical_list: C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human
keywords: IDH1/2 mutation; Postoperative seizure control; Seizure types; Tumor-associated seizure